Home ›
Entities
› academia
› Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
Research article (BMC Health Services Research, 2018) · cited 14× · AI/ML
Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
Summary
Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective is a scholarly article[1].
Key Facts
Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective. Retrieved May 24, 2026, from https://4ort.xyz/entity/budget-impact-analysis-of-the-use-of-extended-half-life-recombinant-factor-viii-efmoroctocog-alfa-for-the-treatment-of-c
MLA“Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/budget-impact-analysis-of-the-use-of-extended-half-life-recombinant-factor-viii-efmoroctocog-alfa-for-the-treatment-of-c.
BibTeX@misc{4ortxyz_budget-impact-analysis-of-the-use-of-extended-half-life-recombinant-factor-viii-efmoroctocog-alfa-for-the-treatment-of-c_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective}}, year = {2026}, url = {https://4ort.xyz/entity/budget-impact-analysis-of-the-use-of-extended-half-life-recombinant-factor-viii-efmoroctocog-alfa-for-the-treatment-of-c}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective — https://4ort.xyz/entity/budget-impact-analysis-of-the-use-of-extended-half-life-recombinant-factor-viii-efmoroctocog-alfa-for-the-treatment-of-c (retrieved 2026-05-24)
